**Deprescribing Psychiatric Medications: Can These Medicines Be Stopped?** Deprescribing is the deliberate and supervised process of tapering off or discontinuing medications when the current or potential benefits have been achieved and the likelihood of symptom relapse is minimal. It is increasingly recognized as an essential aspect of proper prescribing, focusing on dose reduction when necessary and ceasing medication when it is no longer required. This process should not be based solely on theoretical considerations but must also account for the patient's health, current functioning, and, importantly, their values and preferences. Deprescribing aims to apply best practices in prescribing to the discontinuation process. It demands the same level of skill and experience from prescribers, along with support from pharmacists and other healthcare professionals, to achieve optimal outcomes. Central to this process is ensuring that patients' preferences and medication optimization are prioritized. Historically, deprescribing has received little attention in psychiatry. There is a scarcity of research on a structured approach to discontinuing psychiatric medications, except for some early studies on stopping benzodiazepines and in specific populations, such as individuals with learning disabilities. Most research has focused on the initiation of psychiatric medications, with an estimated 1, 000 studies on starting antidepressants and only about 20 on stopping them. This imbalance in research is not unique to psychiatry; other medical specialties, like cardiology, are also re-evaluating long-term medication continuation. **Research and Guideline Development in Deprescribing** In recent years, there has been a significant surge of interest in psychiatric deprescribing. Numerous studies have been conducted or are ongoing to explore reducing and stopping antipsychotics in first and multiple-episode psychotic conditions in various countries, including Taiwan, France, Denmark, the Netherlands, England, Australia, and Germany. This research includes the formation of an international research consortium. Some of these studies are investigating gradual or hyperbolic dose reductions. Concurrently, studies are being conducted in the UK, the Netherlands, and Australia to assist patients in discontinuing antidepressants, with several published studies examining alternatives to antidepressant treatments. There has been growing interest in the process of stopping medications based on their pharmacological properties, as well as in the practical methods for making gradual dose reductions (such as using compounded tablets in very small doses). Additionally, there has been an increased focus on the non-pharmacological aspects of reducing and discontinuing medication, including the positive and negative impacts on people's lives, as well as the barriers and facilitators involved. Simultaneously, there has been rising institutional interest in deprescribing in some countries. In the UK, the Royal College of Psychiatrists has issued guidance on safely stopping antidepressants, benzodiazepines, z-drugs, opioids, and gabapentinoids. In England, the National Health Service (NHS) has implemented structured medication reviews to reduce the use of unnecessary medications, including some psychiatric drugs. The Department of Health and Social Care has been tasked with expanding deprescribing capacity within the NHS. Many clinicians have expressed interest in deprescribing and in receiving training on its practice. In the UK, 75% of clinicians working in first-episode psychosis services believed that early discontinuation of antipsychotic medication was beneficial for most patients. Among patients with multiple psychotic episodes, British psychiatrists reported feeling comfortable supporting about 20% of their patients in discontinuing antipsychotics, with a minority of psychiatrists comfortable with supporting higher proportions. In a survey, 68% of GPs expressed a desire for more training on the withdrawal effects of antidepressants. Notably, in Norway, government directives have led to the establishment of 'drug-free' wards, where deprescribing is a central activity. Several dedicated psychiatric drug deprescribing services have been established worldwide, either in public or private healthcare settings or run by NGOs partnered with health systems. Furthermore, several academics and psychiatrists have shared their personal experiences of discontinuing psychiatric medication, often highlighting that this process was far more challenging than suggested by the published literature or their training. Dr. Shariq Qureshi, a leading psychiatrist in Jaipur, specializes in treating Depression, anxiety, OCD, migraines, headaches disorders. He also offers marriage counseling and thearpies. Dr. Shariq uses medications such as antidepressants, mood stabilisers, and beta-blockers to ensure best treatment.